GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older - GSK
  GSK and Spero Halt UTI Treatment Trial Early After Meeting Efficacy Goals - geneonline.com
  GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win - Fierce Biotech
  GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold? - Nasdaq
  GSK applies to EU regulator for expanded use of RSV vaccine - Reuters
  GSK closer to Japanese Arexvy label expansion - The Pharma Letter
  GSK’s RSV Vaccine Expansion Approved by Japan’s Health Ministry - TipRanks
  GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development - GSK